Regular Article
Inhibition of Angiogenesis by Somatostatin and Somatostatin-like Compounds Is Structurally Dependent

https://doi.org/10.1006/jsre.1993.1167Get rights and content

Abstract

We have previously demonstrated that somatostatin analogues SMS 201-995 and RC-160 inhibit angiogenesis using the chorioallantoic membrane (CAM) of the developing chicken embryo. In this study, we evaluated the ability of native somatostatin 14 and nine somatostatin analogues to inhibit angiogenesis. Two-millimeter methylcellulose disks containing 50 μg of somatostatin or somatostatin analogue were implanted on the CAM of 6- to 7-day-old shell-less chick embryos. Inhibition of blood vessel growth was visually assessed and graded in the region of the disk 24-36 hr following implementation. The analogues SMS 201-995 and RC160 showed statistically significant inhibition of neovascularization when compared to native somatostatin 14. The amino acid hornology comparison of the nine analogues revealed that individual differences in their abilities to inhibit angiogenesis may be structurally dependent.

References (0)

Cited by (110)

  • Prevalence of metabolic syndrome in cirrhotics with gastric antral vascular ectasia

    2022, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
    Citation Excerpt :

    In fact, there are several cases that treat refractory GAVE with thalidomide, a potent anti-VEGF agent [25–27]. Octreotide is known to suppress angiogenesis factors in addition to gastrin and has also been shown to have some success in GAVE treatment [27–29]. Metabolic syndrome may help link the presence of cirrhosis in these patients since the major cause of cirrhosis in GAVE patients was NASH: a common presentation in metabolic syndrome.

  • Systemic Octreotide Therapy in Prevention of Gastrointestinal Bleeds Related to Arteriovenous Malformations and Obscure Etiology in Atrial Fibrillation

    2017, JACC: Clinical Electrophysiology
    Citation Excerpt :

    OCT, a synthetic analogue of somatostatin, has been studied in AVM-related GI bleeding. It acts by inhibition of angiogenesis (24). Indeed, disappearance or decrease in the size of AVMs has been reported with OCT therapy (25).

  • Gastrointestinal Angiodysplasia: Diagnosis and Management

    2017, Gastrointestinal Endoscopy Clinics of North America
    Citation Excerpt :

    Somatostatin analogues constitute a proposed medical therapy for symptomatic GIAD.38 There are several mechanisms for the effect of somatostatin analogues, including inhibition of angiogenesis, decreased duodenal and splanchnic blood flow, increased vascular resistance, enhanced platelet aggregation,38–44 and reduced portal and mesenteric blood flow via inhibition of vasodilator peptides.45 Rossini and colleagues38 performed the first study evaluating somatostatin analogues for treatment of bleeding GIADs.

View all citing articles on Scopus
View full text